| Officer | Age | In this role | Source |
|---|---|---|---|
|
Erez Raphael
Also a director
Chief Executive Officer and Director
|
51 | Not stated | |
|
Zvi Ben David
Chief Financial Officer, Treasurer and Secretary
|
64 |
Since 2015
11 years
|
|
|
Chen Franco-Yehuda
Chief Financial Officer
Title from the Form 4 dated Sep 24, 2026
|
Not stated | Not stated | |
|
Lara Ann Sherman
Chief Operating Officer
Title from the Form 3 dated Sep 24, 2026
|
Not stated | Not stated |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Dec 22, 2025 · updated by the 8-Ks of Apr 13, 2026, Sep 4, 2026, and Nov 6, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2024 pay | Source |
|---|---|---|---|---|---|---|---|
|
Yoav Shaked
Board chair
|
54 | Not stated | Independent |
Audit Committee
Compensation Committee
Nominating and Corporate Governance Committee
|
Endospan Ltd., Vibrant Ltd., G&G Biotechnology Ltd., Orasis Pharmaceuticals, Ltd. | $168,700 | |
|
John R. Palumbo
Joined Apr 10, 2026
Board chair
|
- | - | - | - | - | - | |
|
Erez Raphael
CEO
|
51 |
2014
11 years
|
Not stated | None stated | None stated | Paid as CEO | |
|
Dennis Matheis
|
65 |
2020
5 years
|
Independent |
Audit Committee
Nominating and Corporate Governance Committee · Chair
|
None stated | $135,100 | |
|
Hila Karah
|
57 |
2014
11 years
|
Independent |
Compensation Committee
|
Intec Pharma, Cyren Ltd | $135,100 | |
|
Dennis M. McGrath
|
68 |
2013
12 years
|
Independent |
Audit Committee · Chair
Compensation Committee · Chair
|
Citius Oncology, Inc., Citius Pharmaceuticals, Inc. | $204,400 | |
|
Adam Stern
|
61 |
2020
5 years
|
Not stated | None stated | Aerami Therapeutics Holdings, Matinas BioPharma Holdings, Inc., Adgero Biopharmaceuticals Holdings, Hydrofarm Holdings Group, Inc. | $130,100 |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
Rather than show a list that might be incomplete, we show nothing. They are in the proxy filed Dec 22, 2025, in its related person transactions section.
Read them in the proxyLoading...